Mivael Olivera

1.5k total citations · 2 hit papers
31 papers, 852 citations indexed

About

Mivael Olivera is a scholar working on Oncology, Obstetrics and Gynecology and Epidemiology. According to data from OpenAlex, Mivael Olivera has authored 31 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Obstetrics and Gynecology and 9 papers in Epidemiology. Recurrent topics in Mivael Olivera's work include Endometrial and Cervical Cancer Treatments (14 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cervical Cancer and HPV Research (6 papers). Mivael Olivera is often cited by papers focused on Endometrial and Cervical Cancer Treatments (14 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cervical Cancer and HPV Research (6 papers). Mivael Olivera collaborates with scholars based in Peru, United States and Italy. Mivael Olivera's co-authors include Coraline Dubot, Vincent Castonguay, Pamela Salman, Vanessa Samouëlian, Ronnie Shapira‐Frommer, Mahmut Gümüş, Domenica Lorusso, Krishnansu S. Tewari, Bradley J. Monk and Kan Li and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Mivael Olivera

28 papers receiving 840 citations

Hit Papers

Pembrolizumab for Persist... 2021 2026 2022 2024 2021 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
  2. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mivael Olivera Peru 10 481 385 244 232 150 31 852
M. Valeria Cáceres Argentina 5 378 0.8× 316 0.8× 191 0.8× 194 0.8× 119 0.8× 12 668
Vincent Castonguay Canada 11 563 1.2× 415 1.1× 250 1.0× 239 1.0× 229 1.5× 43 1.0k
Sarper Toker United States 4 354 0.7× 299 0.8× 189 0.8× 178 0.8× 115 0.8× 13 634
Pamela Salman United States 11 646 1.3× 382 1.0× 251 1.0× 253 1.1× 190 1.3× 22 1.1k
Arkhipov Alexander Russia 3 352 0.7× 295 0.8× 185 0.8× 175 0.8× 108 0.7× 4 629
Steven DeCesare United States 9 243 0.5× 260 0.7× 205 0.8× 219 0.9× 141 0.9× 13 695
Roberta Tana Italy 17 183 0.4× 399 1.0× 195 0.8× 205 0.9× 81 0.5× 22 803
James Kauderer United States 15 246 0.5× 794 2.1× 187 0.8× 198 0.9× 84 0.6× 25 1.2k
Noriko Seki Japan 17 332 0.7× 449 1.2× 124 0.5× 108 0.5× 66 0.4× 39 892
Lynne Eaton United States 11 223 0.5× 663 1.7× 164 0.7× 272 1.2× 180 1.2× 17 969

Countries citing papers authored by Mivael Olivera

Since Specialization
Citations

This map shows the geographic impact of Mivael Olivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mivael Olivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mivael Olivera more than expected).

Fields of papers citing papers by Mivael Olivera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mivael Olivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mivael Olivera. The network helps show where Mivael Olivera may publish in the future.

Co-authorship network of co-authors of Mivael Olivera

This figure shows the co-authorship network connecting the top 25 collaborators of Mivael Olivera. A scholar is included among the top collaborators of Mivael Olivera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mivael Olivera. Mivael Olivera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olivera, Mivael, et al.. (2025). Decreased racial disparities in sepsis mortality after an order set–driven initiative: An analysis of 8151 patients. Academic Emergency Medicine. 32(6). 598–603.
2.
Ruiz, Rossana, Claudio Flores, Natalia Valdiviezo, et al.. (2024). Clinical and outcome patterns in epithelial ovarian cancer (EOC) within a Latin American cohort.. Journal of Clinical Oncology. 42(16_suppl). e23308–e23308. 1 indexed citations
3.
Colombo, Nicoletta, Coraline Dubot, Kazuki Hasegawa, et al.. (2024). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Annals of Oncology. 36(1). 65–75. 9 indexed citations
4.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
5.
6.
7.
8.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2022). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Obstetrical & Gynecological Survey. 77(1). 30–31. 10 indexed citations
9.
Guio, Heinner, Víctor Aliaga-Tobar, Marco Galarza, et al.. (2022). Comparative Profiling of Circulating Exosomal Small RNAs Derived From Peruvian Patients With Tuberculosis and Pulmonary Adenocarcinoma. Frontiers in Cellular and Infection Microbiology. 12. 909837–909837. 10 indexed citations
10.
11.
Tewari, Krishnansu S., Nicoletta Colombo, Bradley J. Monk, et al.. (2022). Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.. Journal of Clinical Oncology. 40(16_suppl). 5506–5506. 9 indexed citations
12.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2021). LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study. Annals of Oncology. 32. S1307–S1308. 4 indexed citations
13.
Ruiz, Rossana, Ebert Poquioma, Mivael Olivera, et al.. (2020). Lung Cancer in Peru. Journal of Thoracic Oncology. 15(6). 891–898. 6 indexed citations
14.
Ruiz, Rossana, et al.. (2020). Epidemiology of thymic epithelial tumors: 22‐years experience from a single‐institution. Thoracic Cancer. 12(4). 420–425. 4 indexed citations
15.
Ruiz, Rossana, et al.. (2019). P2.05 Real World Data on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Use in Advanced Non-small Cell Lung Cancer from a Latin American Cohort. Journal of Thoracic Oncology. 14(11). S1187–S1187. 1 indexed citations
16.
Ruiz, Rossana, et al.. (2019). P2.16-25 Epidemiology of Advanced Lung Cancer in Peru. Journal of Thoracic Oncology. 14(10). S875–S875. 2 indexed citations
17.
Más, Luís, Mivael Olivera, Zaida Morante, et al.. (2018). Citorreducción óptima en cáncer de ovario avanzado tratado con paclitaxel a dosis densa y carboplatino seguido de cirugía de intervalo en el Instituto Nacional de Enfermedades Neoplásicas del Perú. Revista Peruana de Medicina Experimental y Salud Pública. 35(1). 46–46. 2 indexed citations
18.
Ruiz, Rossana, Eloy Ruíz, Mivael Olivera, et al.. (2017). Características clínico-patológicas y sobrevida en mujeres jóvenes con cáncer cervical: análisis retrospectivo del Instituto Nacional de Enfermedades Neoplásicas. Revista Peruana de Medicina Experimental y Salud Pública. 34(2). 218–218. 8 indexed citations
19.
Taberna, Miren, Cinta Hierro, Marc Díez, et al.. (2013). PO-081: Late Toxicity After Radical Treatment for Locally Advanced Head-and-Neck Carcinomas.. Radiotherapy and Oncology. 106. S34–S35. 1 indexed citations
20.
Gómez, Henry, Joseph A. Pinto, Mivael Olivera, et al.. (2010). Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. The Breast. 20(1). 39–45. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Valeria Cáceres Breakdown of academic impact, for papers by Vincent Castonguay Breakdown of academic impact, for papers by Sarper Toker Breakdown of academic impact, for papers by Pamela Salman Breakdown of academic impact, for papers by Arkhipov Alexander Breakdown of academic impact, for papers by Steven DeCesare Breakdown of academic impact, for papers by Roberta Tana Breakdown of academic impact, for papers by James Kauderer Breakdown of academic impact, for papers by Noriko Seki Breakdown of academic impact, for papers by Lynne Eaton
Rankless by CCL
2026